Transplant Reports : Open Access
Open Access

Lung transplantation reports; Life quality; Older adults

Introduction

Performing lung transplants in older adults presents several challenges that must be carefully navigated by clinicians and transplant teams. One of the primary concerns is the presence of age-related comorbidities, such as cardiovascular disease, diabetes, and renal insufficiency, which may increase the risk of perioperative complications and impact post-transplant outcomes. Additionally, older adults may have reduced physiologic reserve and functional capacity, making them more susceptible to surgical stress and prolonged recovery periods following transplantation [1-3].

Methodology

Another challenge is the increased incidence of donor lung dysfunction associated with older donor age, which may compromise graft function and contribute to post-transplant complications. Furthermore, older adults may have a higher prevalence of pre-existing lung diseases, such as chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD), which can further complicate the transplant process and influence long-term outcomes. Immunosenescence, or age-related decline in immune function, is another factor that can impact the success of lung transplantation in older adults. Immunosenescence may contribute to an increased risk of infection, impaired wound healing, and heightened susceptibility to rejection post-transplantation. Therefore, careful patient selection, comprehensive preoperative evaluation, and individualized immunosuppressive regimens are essential to optimize outcomes in this patient population [4-6]. Despite these challenges, recent studies have demonstrated favorable outcomes in older adults undergoing lung transplantation. While older age is associated with an increased risk of perioperative complications and mortality, survival rates following lung transplantation in older adults have steadily improved over the years. Moreover, older adults who undergo lung transplantation experience significant improvements in quality of life, functional status, and symptom control, with many achieving long-term graft survival and meaningful survival outcomes.

It is important to note that successful lung transplantation in older adults requires a multidisciplinary approach, encompassing comprehensive preoperative assessment, meticulous surgical technique, tailored immunosuppressive therapy, and ongoing post-transplant care. Close collaboration between transplant teams, geriatric specialists, and rehabilitation professionals is essential to address the unique needs and challenges faced by older transplant recipients throughout the transplant journey [7-9]. Looking ahead, there are several opportunities for further advancing lung transplantation in older adults. One area of focus is optimizing donor selection and organ allocation strategies to maximize graft quality and minimize the risk of primary graft dysfunction in older recipients. Advances in ex-vivo lung perfusion (EVLP) techniques and donor lung assessment tools offer promise for improving donor lung evaluation and enhancing transplant outcomes in older adults.

Furthermore, there is growing interest in exploring novel immunomodulatory therapies and strategies to mitigate the risks of rejection, infection, and immunosenescence in older transplant recipients. Targeted approaches, such as induction immunosuppression and personalized immunosuppressive regimens, may help minimize the reliance on long-term immunosuppression and reduce the burden of immunosuppressive-related complications in older adults [10].

Discussion

In conclusion, lung transplantation in older adults represents a complex yet increasingly feasible therapeutic option for individuals with end-stage lung disease. While challenges such as age-related comorbidities, donor lung quality, and immunosenescence exist, recent advancements in surgical techniques, immunosuppressive therapies, and perioperative management have contributed to improved outcomes in this patient population. By embracing a multidisciplinary approach and leveraging emerging technologies and treatment modalities, clinicians can continue to optimize the outcomes and quality of life for older adults undergoing lung transplantation. The discussion surrounding lung transplantation in older adults underscores both the opportunities and challenges inherent in addressing the unique needs of this patient population. On one hand, the increasing age of transplant recipients presents several challenges, including age-related comorbidities, reduced physiologic reserve, and immunosenescence. These factors can contribute to higher perioperative risks, including surgical complications, infections, and prolonged recovery periods. Additionally, older adults may have a higher prevalence of pre-existing lung diseases, further complicating the transplant process and influencing long-term outcomes. However, despite these challenges, recent reports have shown favorable outcomes in older adults undergoing lung transplantation.

Studies have demonstrated significant improvements in quality of life, functional status, and symptom control following lung transplantation in older adults. Many older recipients achieve meaningful survival outcomes and long-term graft survival, highlighting the potential benefits of transplantation in this population. Furthermore, advancements in surgical techniques, perioperative management, and immunosuppressive therapies have contributed to improved outcomes in older transplant recipients.

Additionally, ongoing research efforts are focused on optimizing donor selection, organ allocation strategies, and immunomodulatory therapies specifically tailored to the needs of older adults. By addressing age-related factors and implementing personalized treatment approaches, clinicians can further enhance the success rates and long-term outcomes of lung transplantation in older adults.

Overall, while challenges persist, the growing body of evidence supports the feasibility and effectiveness of lung transplantation in older adults. By embracing a multidisciplinary approach and leveraging advancements in transplant care, clinicians can continue to improve the quality of life and survival outcomes for older adults with end-stage lung disease undergoing transplantation.

Conclusion

In conclusion, the reports on lung transplantation in older adults highlight both the challenges and opportunities in addressing the unique needs of this patient population. While older age presents inherent risks, including age-related comorbidities and immunosenescence, recent studies have shown favorable outcomes following lung transplantation in older adults. Significant improvements in quality of life, functional status, and survival rates underscore the potential benefits of transplantation in this demographic. Despite challenges such as donor lung quality and perioperative risks, advancements in surgical techniques, immunosuppressive therapies, and perioperative management have contributed to improved outcomes in older transplant recipients. Moreover, ongoing research efforts aimed at optimizing donor selection, organ allocation, and immunomodulatory therapies offer promise for further enhancing transplant outcomes in older adults.

By embracing a multidisciplinary approach and leveraging emerging technologies and treatment modalities, clinicians can continue to improve the success rates and long-term outcomes of lung transplantation in older adults. Ultimately, lung transplantation remains a viable therapeutic option for older adults with end-stage lung disease, offering the potential for improved quality of life and extended survival.

References

1. Delgado JF, Reyne AG, de Dios S, López-Medrano F, Jurado A, et al. (2015) Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation. J Heart Lung Transplant 3:1112-1119.

Indexed at, Google Scholar, Crossref

2. Raffa GM, Di Gesaro G, Sciacca S, Tuzzolino F, Turrisi M, et al. (2016) Heart transplant program at IRCCS-ISMETT: Impact of mechanical circulatory support on pre- and post -transplant survival. Int J Cardiol 219: 358-361.

Indexed at, Google Scholar, Crossref

3. Zielińska K, Kukulski L, Wróbel M, Przybyłowski P, Rokicka D, et al. (2022) Carbohydrate Metabolism Disorders in Relation to Cardiac Allograft Vasculopathy (CAV) Intensification in Heart Transplant Patients According to the Grading Scheme Developed by the International Society for Heart and Lung Transplantation (ISHLT). Ann Transplant 27: 933420.

Indexed at, Google Scholar, Crossref

4. Conway J, Manlhiot C, Kirk R, Edwards LB, McCrindle BW, et al. Mortality and morbidity after retransplantation after primary heart transplant in childhood: an analysis from the registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 33: 241-51.

Indexed at, Google Scholar, Crossref

5. R D Vanderlaan, C Manlhiot, L B Edwards, J Conway, B W McCrindle, et al. (2015) Risk factors for specific causes of death following pediatric heart transplant: An analysis of the registry of the International Society of Heart and Lung Transplantation. Pediatr Transplant 19: 896-905.

Indexed at, Google Scholar, Crossref

6. Kitamura S (2012) Heart transplantation in Japan: a critical appraisal for the results and future prospects. Gen Thorac Cardiovasc Surg 60: 639-644.

Indexed at, Google Scholar, Crossref

7. Wever-Pinzon O, Edwards LB, Taylor DO, Kfoury AG, Drakos SG, et al. (2017) Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 36: 407-417.

Indexed at, Google Scholar, Crossref

8. Saczkowski R, Dacey C, Bernier PL (2010) Does ABO-incompatible and ABO-compatible neonatal heart transplant have equivalent survival. Interact Cardiovasc Thorac Surg 10: 1026-1033.

Indexed at, Google Scholar, Crossref

9. Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, et al. (2014) Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. J Thorac Cardiovasc Surg 147: 462-468.

Indexed at, Google Scholar, Crossref

10. Sivathasan C, Lim CP, Kerk KL, Sim DK, Mehra MR, et al. (2017) Mechanical circulatory support and heart transplantation in the Asia Pacific region. J Heart Lung Transplant 36: 13-18.

Indexed at, Google Scholar, Crossref